2026 ICD-10-CM Diagnosis Code C32.1Malignant neoplasm of supraglottis
ICD-10-CM Codes›C00–D49›C30-C39›C32
- Billable — Valid for Submission
- Risk Adjusts — HCC 21
- Chronic Condition
C32.1 is a billable ICD-10-CM diagnosis code for malignant neoplasm of supraglottis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 11 through 13, 146 through 148. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Head and neck cancers - laryngeal.
For Medicare Advantage risk adjustment, C32.1 maps to CMS-HCC Category 21 (Lymphoma and Other Cancers) under the V28 model, adding a risk factor of about 0.671 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C32.1 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Carcinoma of larynx
- Carcinoma of supraglottis
- Malignant neoplasm of epiglottis
- Malignant neoplasm of false cord
- Malignant neoplasm of infrahyoid epiglottis
- Malignant neoplasm of junctional region of epiglottis
- Malignant neoplasm of laryngeal aspect of aryepiglottic fold
- Malignant neoplasm of laryngeal aspect of interarytenoid fold
- Malignant neoplasm of supraglottis
- Malignant neoplasm of suprahyoid epiglottis
- Malignant neoplasm of ventricle of larynx
- Neoplasm of false vocal cord
- Neoplasm of infrahyoid epiglottis
- Neoplasm of laryngeal aspect of aryepiglottic fold
- Neoplasm of laryngeal aspect of interarytenoid fold
- Neoplasm of laryngeal surface of epiglottis
- Neoplasm of suprahyoid epiglottis
- Neoplasm of ventricle of larynx
- Primary carcinoma of larynx
- Primary carcinoma of supraglottis
- Primary malignant neoplasm of epiglottis
- Primary malignant neoplasm of false vocal cord
- Primary malignant neoplasm of laryngeal aspect of aryepiglottic fold
- Primary malignant neoplasm of laryngeal surface of epiglottis
- Primary malignant neoplasm of soft tissues of neck
- Primary malignant neoplasm of supraglottis
- Primary squamous cell carcinoma of supraglottis
- Squamous cell carcinoma of epiglottis
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Malignant neoplasm of aryepiglottic fold or interarytenoid fold, laryngeal aspect
- Malignant neoplasm of epiglottis (suprahyoid portion) NOS
- Malignant neoplasm of extrinsic larynx
- Malignant neoplasm of false vocal cord
- Malignant neoplasm of posterior (laryngeal) surface of epiglottis
- Malignant neoplasm of ventricular bands
Type 2 Excludes
- malignant neoplasm of anterior surface of epiglottis C10.1
- malignant neoplasm of aryepiglottic fold or interarytenoid fold, hypopharyngeal aspect C13.1
- malignant neoplasm of aryepiglottic fold or interarytenoid fold, marginal zone C13.1
- malignant neoplasm of aryepiglottic fold or interarytenoid fold NOS C13.1
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Epiglottis
a thin leaf-shaped cartilage that is covered with laryngeal mucosa and situated posterior to the root of the tongue and hyoid bone. during swallowing, the epiglottis folds back over the larynx inlet thus prevents foods from entering the airway.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
| Site | Malig. Primary | Malig. Secondary | Ca in situ | Benign | Uncertain | Unspec. |
|---|---|---|---|---|---|---|
| aryepiglottic fold › laryngeal aspect | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| cartilage (articular) (joint) NEC [See Also: Neoplasm, bone] › epiglottis | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| cord (true) (vocal) › false | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| epiglottis | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| epiglottis › posterior (laryngeal) surface | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| epiglottis › suprahyoid portion | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| interarytenoid fold › laryngeal aspect | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| larynx, laryngeal NEC › aryepiglottic fold | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| larynx, laryngeal NEC › extrinsic NEC | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| larynx, laryngeal NEC › interarytenoid fold | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| larynx, laryngeal NEC › ventricular band | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| supraglottis | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| ventricular band of larynx | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
| vocal cords (true) › false | C32.1 | C78.39 | D02.0 | D14.1 | D38.0 | D49.1 |
Patient EducationClinical
Throat Cancer
Throat cancer is a type of head and neck cancer. Throat cancer has different names, depending on which part of the throat is affected. The different parts of your throat are called the oropharynx, the hypopharynx, the nasopharynx, and the larynx, or voice box.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C32.1 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C32.1Overview
What is the ICD-10 code for malignant neoplasm of supraglottis?
The ICD-10-CM code for malignant neoplasm of supraglottis is C32.1 (sometimes written as C321). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is C32.1 (Malignant neoplasm of larynx) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of supraglottis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C32.1 group to?
When malignant neoplasm of supraglottis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 11, 12, 13, 146, 147, 148, with relative weights from 0.7971 to 5.4541 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of C32.1?
Under the General Equivalence Mappings, malignant neoplasm of supraglottis converts to ICD-9-CM 161.1 (malig neo supraglottis). The mapping is a direct match.
What HCC is C32.1?
C32.1 (malignant neoplasm of supraglottis) maps to CMS-HCC Category 21 (Lymphoma and Other Cancers), commonly written as HCC 21, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 11 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.
Does C32.1 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C32.1 adds a risk adjustment factor of about 0.671 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.493 to 0.739 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, and HCC 20) supersedes it when both are reported. See the full factor table on the HCC 21 category page.
